June 3 (Bloomberg) -- The next generation of experimental immune-boosting drugs from Merck, Bristol-Myers and Roche are producing such promising early results that doctors are openly speculating that some patients with the deadliest form of skin cancer may be cured. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)
Dow at 20,000 Would Be `Fair Market Value,' Siegel Says
March 5 -- Jeremy Siegel, a finance professor at the University of Pennsylvania's Wharton School, talks about the outlook for the U.S. stock market. Siegel speaks with Betty Liu on Bloomberg Television's "In the Loop."
How Secure Was Hillary Clinton’s Personal Email System?
Euro Is Now Positive Versus the Dollar
J Crew Opens Latest International Store in Paris
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: